Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma
11 nov. 2022 12h00 HE
|
Candel Therapeutics
Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with no significant added toxicity compared to standard of careSystemic immune activation was observed...
Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
10 nov. 2022 08h00 HE
|
Candel Therapeutics
Discovery collaboration underway with Center for Cellular Immunotherapies Lab at University of Pennsylvania to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy Candidates in...
Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNO
07 nov. 2022 08h00 HE
|
Candel Therapeutics
NEEDHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced new...
Candel Therapeutics Upcoming Investor Conference Participation for November
01 nov. 2022 08h00 HE
|
Candel Therapeutics
NEEDHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that...
Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models
26 oct. 2022 08h00 HE
|
Candel Therapeutics
Goal of evaluating combination of novel viral immunotherapies with aim to potentiate CAR-T cell therapies in solid tumors Employs Candel’s enLIGHTEN™ Discovery Platform Both parties retain rights in...
Candel Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for CAN-2409 in Glioma
15 sept. 2022 08h00 HE
|
Candel Therapeutics
NEEDHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL) (Candel or the Company), a late clinical stage biopharmaceutical company developing novel oncolytic viral...
Candel Therapeutics Announces Two Executive Leadership Appointments
07 sept. 2022 08h00 HE
|
Candel Therapeutics
Jason A. Amello joins Candel as Chief Financial OfficerGarrett Nichols, MD, MS, joins Candel as Chief Medical Officer NEEDHAM, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc....
Candel Therapeutics Upcoming Investor Conference Participation
06 sept. 2022 08h00 HE
|
Candel Therapeutics
NEEDHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today...
Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
05 août 2022 08h00 HE
|
Candel Therapeutics
NEEDHAM, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight...
Candel Therapeutics Appoints Three New Members to its Board of Directors
01 août 2022 08h00 HE
|
Candel Therapeutics
Gary Nabel, MD, PhD, Chief Innovation Officer of OPKO and Chief Executive Officer, ModeX Therapeutics, Inc., an OPKO Health companyJoseph Papa, Chief Executive Officer of Bausch + Lomb...